Athira Pharma, Inc.
ATHA
$0.36
$0.01885.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.75M | -96.94M | -109.22M | -113.45M | -116.19M |
| Total Depreciation and Amortization | 971.00K | 970.00K | 972.00K | 973.00K | 975.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.94M | 10.78M | 10.52M | 9.73M | 9.40M |
| Change in Net Operating Assets | -17.20M | -11.98M | 282.00K | 4.34M | 5.45M |
| Cash from Operations | -86.03M | -97.17M | -97.45M | -98.41M | -100.36M |
| Capital Expenditure | -28.00K | -33.00K | -33.00K | -63.00K | -68.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.47M | 54.86M | 64.07M | 66.75M | 72.68M |
| Cash from Investing | 34.44M | 54.83M | 64.03M | 66.68M | 72.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 194.00K | 194.00K | 312.00K | 300.00K | 394.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 194.00K | 194.00K | 312.00K | 300.00K | 394.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -51.40M | -42.15M | -33.11M | -31.43M | -27.36M |